Bangladesh Pharma Sector Faces Rising Energy Costs and Challenges
A recent exchange meeting in Tejgaon highlighted how soaring electricity and fuel prices are driving up local medicine production costs. Industry leaders warned that these escalating expenses and regulatory burdens threaten profit margins.
A high-level exchange meeting focusing on the progress, challenges, and prospects of the country's pharmaceutical industry was held on Monday at the office of the Bangladesh Association of Pharmaceutical Industries (BAPI) in Tejgaon, Dhaka. The event brought together representatives from the Bangladesh Association of Pharmaceutical Industries (BAPI) and the Bangladesh Health Reporters Forum (BHRF) to discuss the current economic pressures facing domestic medicine manufacturers.
During the discussions, industry representatives detailed the severe financial strains caused by surging utility expenses. A central concern raised at the meeting was the dramatic escalation in electricity pricing. According to the presented data, the official government rate for electricity has spiked significantly, surging from 15 Taka to 42 Taka, which has heavily burdened factory operations across the sector.
In addition to electricity rate hikes, manufacturers are grappling with severe infrastructural and fuel-related hurdles. Due to an ongoing shortage of regular gas supplies, pharmaceutical production facilities are frequently forced to rely on diesel to run their generators, introducing an additional layer of unpredictable operational costs.
Halimuzzaman, speaking at the event, addressed the compounding nature of these financial pressures. He stated, "Energy is one of them, which we are seeing with our eyes. And the rest of the things that are there, we are not seeing them now. We do not even understand how much that cost actually is."
Halimuzzaman further elaborated on how these accumulated expenses directly impact the manufacturing sector, noting that additional regulatory and testing demands have also intensified. While manufacturers previously had to conduct five tests, the required number of tests has now increased to eight. Furthermore, processing certain medications now requires identifying anywhere from 18 to 20 different types of impurities.
Concluding his remarks on the broader economic viability of the industry, Halimuzzaman emphasized the ultimate toll of these rising overheads. He stated, "All of these are actually the production costs of medicines. But this is a continuous process. Amidst this, if the cost of fuel continues to increase in this manner, then it will certainly have an impact on our profit."
